Pulmonx (LUNG) has upsized its IPO from 6.67M to 10M shares and raised the price range to $17-$18 vs. prior range of $14-$16 per share.
Proceeds will be used to hire sales and marketing people, fund R&D, to pay a success fee to Oxford of $1.9M and for working capital.
Pulmonx is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD).
https://seekingalpha.com/news/3618300-pulmonx-raises-price-range-of-upsized-ipo-of-10m-shares
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.